{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:08:45Z","timestamp":1789664925043,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.breast.2025.104687","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:02:39Z","timestamp":1767027759000},"page":"104687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Age-stratified toxicity patterns of CDK4\/6 inhibitors in older women with breast cancer: Disproportionality analysis from the FAERS database"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-6393","authenticated-orcid":false,"given":"Bahad\u0131r","family":"K\u00f6yl\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu\u011fra Han","family":"Esen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cevat \u0130lteri\u015f","family":"K\u0131k\u0131l\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Kemik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyda","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eahin","family":"La\u00e7in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Tural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Tunal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclistan","family":"Bahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Sel\u00e7ukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2025.104687_bib1","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin n.d.;n\/a. https:\/\/doi.org\/10.3322\/caac.21834.."},{"key":"10.1016\/j.breast.2025.104687_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.56142","article-title":"Incidence rate trends of breast cancer overall and by molecular subtype by race and ethnicity and age","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2025.104687_bib3","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/1055-9965.EPI-18-0098","article-title":"Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions","volume":"27","author":"Pfeiffer","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.breast.2025.104687_bib4","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2025.104687_bib5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2025.104687_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.breast.2025.104687_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.916682","article-title":"Cyclin-dependent kinase inhibitors in malignant hematopoiesis","volume":"12","author":"Schirripa","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2025.104687_bib8","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/ijms21061960","article-title":"The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer","volume":"21","author":"Ding","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2025.104687_bib9","first-page":"5590599","article-title":"Side effects of CDK4\/6 inhibitors in the treatment of HR+\/HER2\u2212 advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Yang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.breast.2025.104687_bib10","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.3390\/cancers16162869","article-title":"Profiling the cardiovascular toxicities of CDK4\/6 inhibitors: a real-world pharmacovigilance study","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2025.104687_bib11","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cancers16101838","article-title":"The use of cyclin-dependent kinase 4\/6 inhibitors in elderly breast cancer patients: what do we know?","volume":"16","author":"Giraudo","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2025.104687_bib12","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.breast.2025.104687_bib13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.breast.2025.104687_bib14","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.3390\/ijms21176350","article-title":"CDK4\/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions","volume":"21","author":"Roncato","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2025.104687_bib15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/cpdd.356","article-title":"Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-Dependent solubility, with different food intake conditions","volume":"6","author":"Sun","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.breast.2025.104687_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.breast.2025.104687_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/17425255.3.3.315","article-title":"The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions","volume":"3","author":"Mangoni","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.breast.2025.104687_bib18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1124\/jpet.103.061234","article-title":"The effect of age on P-glycoprotein expression and function in the Fischer-344 rat","volume":"309","author":"Warrington","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.breast.2025.104687_bib19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s11357-024-01245-6","article-title":"Body composition and aging: cross-sectional results from the INSPIRE study in people 20 to 93 years old","volume":"47","author":"Briand","year":"2025","journal-title":"GeroScience"},{"key":"10.1016\/j.breast.2025.104687_bib20","article-title":"Global prevalence of malnutrition in older adults: a comprehensive systematic review and meta-analysis","volume":"9","author":"Salari","year":"2025","journal-title":"Public Health Pract"},{"key":"10.1016\/j.breast.2025.104687_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1278682","article-title":"Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4\/6 inhibitors: a pharmacovigilance study using the World Health Organization's database","volume":"14","author":"Prevost","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.breast.2025.104687_bib22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s11096-023-01687-6","article-title":"A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases","volume":"46","author":"Takeda","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.breast.2025.104687_bib23","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/med.21769","article-title":"How selective are clinical CDK4\/6 inhibitors?","volume":"41","author":"Hendrychov\u00e1","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.breast.2025.104687_bib24","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1167\/iovs.06-0139","article-title":"Suppression of human lens epithelial cell proliferation by proteasome inhibition, a potential defense against posterior capsular opacification","volume":"47","author":"Awasthi","year":"2006","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.breast.2025.104687_bib25","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1002\/onco.13684","article-title":"Long-Term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone Receptor-Positive\/Human epidermal growth factor receptor 2-Negative advanced breast cancer: updated analysis with up to 5 years of Follow-Up","volume":"26","author":"Finn","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2025.104687_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/cas.13507","article-title":"Palbociclib in combination with letrozole as first\u2010line treatment for advanced breast cancer: a Japanese phase II study","volume":"109","author":"Masuda","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.breast.2025.104687_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/annrheumdis-2014-205566","article-title":"Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression","volume":"75","author":"Hosoya","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.breast.2025.104687_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111370","article-title":"Association between cyclin-dependent kinase 4\/6 inhibitors and nephrotoxicity in patients with breast cancer: a Systematic Review and meta-analysis","volume":"27","author":"Cui","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.breast.2025.104687_bib29","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1177\/10781552211007202","article-title":"Ribociclib induced acute kidney injury: a case report","volume":"27","author":"Gulturk","year":"2021","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.breast.2025.104687_bib30","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ekir.2021.11.033","article-title":"Clinicopathologic features of acute kidney injury associated with CDK4\/6 inhibitors","volume":"7","author":"Gupta","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.breast.2025.104687_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113939","article-title":"Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms","volume":"177","author":"Kim","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.breast.2025.104687_bib32","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1073\/pnas.1424313112","article-title":"Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4\/6 and OCT2 functions","volume":"112","author":"Pabla","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.breast.2025.104687_bib33","article-title":"The deleterious effects of CDK4\/6 inhibition on renal recovery post-acute kidney injury","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2025.104687_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104296","article-title":"Cardiovascular complications of ribociclib in breast cancer patients","volume":"196","author":"Fiste","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.breast.2025.104687_bib35","article-title":"Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+\/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials","volume":"217","author":"Hart","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.breast.2025.104687_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JGO.2019.5.suppl.134","article-title":"The effect of addition of cyclin-dependent kinase 4 & 6 (CDK 4\/6) inhibitor to endocrine therapy in the cardiovascular toxicity in advanced breast cancer patients: a systematic review and meta-analysis","volume":"5","author":"Bebero","year":"2019","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.breast.2025.104687_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","article-title":"CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis","volume":"21","author":"Onesti","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.breast.2025.104687_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103160","article-title":"Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study","volume":"82","author":"Zhu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.breast.2025.104687_bib39","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s12282-020-01207-8","article-title":"Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan","volume":"28","author":"Chen","year":"2021","journal-title":"Breast Cancer Tokyo Jpn"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625009063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625009063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:07:36Z","timestamp":1770998856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625009063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"alternative-id":["S0960977625009063"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104687","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age-stratified toxicity patterns of CDK4\/6 inhibitors in older women with breast cancer: Disproportionality analysis from the FAERS database","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104687"}}